BIOLASE (BIOL) Diolase 10 Cleared by FDA for Use in Additional Markets
BIOLASE, Inc. (NASDAQ: BIOL) announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Corp plc (AMRN) Announces ANCHOR CRL from FDA on Vascepa
- Aeterna Zentaris (AEZS) Announces Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin
- RedHill Biopharma (RDHL) Completes Enrollment in Ph-3 Study of RHB-105 for H. pylori Infection
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!